These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 18084092)
1. Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors. Xu S; McKeever BM; Wisniewski D; Miller DK; Spencer RH; Chu L; Ujjainwalla F; Yamin TT; Evans JF; Becker JW; Ferguson AD Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Dec; 63(Pt 12):1054-7. PubMed ID: 18084092 [TBL] [Abstract][Full Text] [Related]
2. 5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. Plante H; Picard S; Mancini J; Borgeat P Biochem J; 2006 Jan; 393(Pt 1):211-8. PubMed ID: 16144515 [TBL] [Abstract][Full Text] [Related]
3. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337 [TBL] [Abstract][Full Text] [Related]
4. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mancini JA; Prasit P; Coppolino MG; Charleson P; Leger S; Evans JF; Gillard JW; Vickers PJ Mol Pharmacol; 1992 Feb; 41(2):267-72. PubMed ID: 1538707 [TBL] [Abstract][Full Text] [Related]
5. The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein. Mancini JA; Coppolino MG; Klassen JH; Charleson S; Vickers PJ Life Sci; 1994; 54(9):PL137-42. PubMed ID: 8114608 [TBL] [Abstract][Full Text] [Related]
8. Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors. Vickers PJ; Adam M; Charleson S; Abramovitz M; O'Neill G; Mancini JA J Lipid Mediat; 1993; 6(1-3):31-42. PubMed ID: 8357989 [TBL] [Abstract][Full Text] [Related]
9. Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein. Charleson S; Evans JF; Léger S; Perrier H; Prasit P; Wang Z; Vickers PJ Eur J Pharmacol; 1994 May; 267(3):275-80. PubMed ID: 8088366 [TBL] [Abstract][Full Text] [Related]
10. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Ford-Hutchinson AW Trends Pharmacol Sci; 1991 Feb; 12(2):68-70. PubMed ID: 2024291 [TBL] [Abstract][Full Text] [Related]
11. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Dixon RA; Diehl RE; Opas E; Rands E; Vickers PJ; Evans JF; Gillard JW; Miller DK Nature; 1990 Jan; 343(6255):282-4. PubMed ID: 2300173 [TBL] [Abstract][Full Text] [Related]
12. Leukotriene C4 synthase and 5-lipoxygenase activating protein. Regulators of the biosynthesis of sulfido-leukotrienes. Ford-Hutchinson AW Ann N Y Acad Sci; 1994 Nov; 744():78-83. PubMed ID: 7825864 [No Abstract] [Full Text] [Related]
14. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. Prasit P; Belley M; Blouin M; Brideau C; Chan C; Charleson S; Evans JF; Frenette R; Gauthier JY; Guay J J Lipid Mediat; 1993; 6(1-3):239-44. PubMed ID: 8357985 [TBL] [Abstract][Full Text] [Related]
15. 5-lipoxygenase-activating protein is an arachidonate binding protein. Mancini JA; Abramovitz M; Cox ME; Wong E; Charleson S; Perrier H; Wang Z; Prasit P; Vickers PJ FEBS Lett; 1993 Mar; 318(3):277-81. PubMed ID: 8440384 [TBL] [Abstract][Full Text] [Related]
16. The effect of 5-lipoxygenase-activating protein (FLAP) on substrate utilization by 5-lipoxygenase. Vickers PJ; Deluca C; Wong E; Abramovitz M Adv Exp Med Biol; 1997; 400A():145-51. PubMed ID: 9547550 [No Abstract] [Full Text] [Related]
17. Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors. Vickers PJ; Adam M; Charleson S; Coppolino MG; Evans JF; Mancini JA Mol Pharmacol; 1992 Jul; 42(1):94-102. PubMed ID: 1635556 [TBL] [Abstract][Full Text] [Related]
18. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Evans JF; Ferguson AD; Mosley RT; Hutchinson JH Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210 [TBL] [Abstract][Full Text] [Related]